Immucell (ICCC) Cash from Operations Growth (1y) (2011 - 2025)
Immucell (ICCC) Cash from Operations Growth (1y) (2011 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 4.87% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -28.96% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 42.76% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 75.58% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 151.70% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 172.77% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 56.79% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 100.14% |
| 10 | Immucell | 91.19 Mn | 82.33 Mn | 2.44 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 15,915.83% |
| Sep 30, 2025 | -84.97% |
| Jun 30, 2025 | 175.28% |
| Mar 31, 2025 | 276.06% |
| Dec 31, 2024 | 99.58% |
| Sep 30, 2024 | -25.91% |
| Jun 30, 2024 | 185.38% |
| Mar 31, 2024 | 115.15% |
| Dec 31, 2023 | 44.29% |
| Sep 30, 2023 | 59.64% |
| Jun 30, 2023 | -282.46% |
| Mar 31, 2023 | -532.55% |
| Dec 31, 2022 | -320.76% |
| Sep 30, 2022 | -585.75% |
| Jun 30, 2022 | -48.90% |
| Mar 31, 2022 | 202.40% |
| Dec 31, 2021 | 276.26% |
| Sep 30, 2021 | 138.81% |
| Jun 30, 2021 | -24.59% |
| Mar 31, 2021 | -172.72% |